Prostate Cancer Trial, Recruiting (NCT06700057)

Prostate Cancer Trial, Recruiting NCT06700057 Sponsor: Institut Bergonié Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06700057 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 or older.
People with prostate cancer that has spread to other parts of the body, is no longer responding to hormone-lowering treatments, and has high levels of a protein called PSMA on the cancer cells.
People whose prostate cancer has been treated with taxane chemotherapy and at least one of the following hormone-blocking medicines: apalutamide, enzalutamide, darolutamide, or abiraterone-prednisone.
People who are due to start, have recently started, or have already completed a treatment called 177Lu-PSMA-617 (a type of targeted radiation therapy) on or after 1 November 2023.
People who are able to lie still for about one hour during a medical scan.
People who live within approximately two hours' drive of Institut Bergonié (a cancer centre in Bordeaux, France).
People who have not objected to their medical data being used for research purposes.

Who may not be able to join:

No specific exclusion criteria have been listed for this trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Nadège ANIZAN, Institut Bergonié

Phone: +33556333347

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06700057

Sponsor: Institut Bergonié

Phase: Not Applicable

Status: Recruiting

Condition: Prostate Cancer

Trial contact: +33556333347

More information: https://clinicaltrials.gov/study/NCT06700057

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 or older.
People with prostate cancer that has spread to other parts of the body, is no longer responding to hormone-lowering treatments, and has high levels of a protein called PSMA on the cancer cells.
People whose prostate cancer has been treated with taxane chemotherapy and at least one of the following hormone-blocking medicines: apalutamide, enzalutamide, darolutamide, or abiraterone-prednisone.
People who are due to start, have recently started, or have already completed a treatment called 177Lu-PSMA-617 (a type of targeted radiation therapy) on or after 1 November 2023.
People who are able to lie still for about one hour during a medical scan.
People who live within approximately two hours' drive of Institut Bergonié (a cancer centre in Bordeaux, France).
People who have not objected to their medical data being used for research purposes.

Who may not be able to join:

No specific exclusion criteria have been listed for this trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Institut Bergonié

Registry

ClinicalTrials.gov

Start date

1 November 2023

Est. completion

30 November 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Median of total absorbed-dose of 177Lu-PSMA-617 at total tumor volume as a function of prostate-antigen specific (PSA) response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov